Medtronic has reported new clinical and real-world data on fixed meal dosing and real-world time in range (TIR) to support the effectiveness of MiniMed 780G insulin pump system across a wide range of users.
The Ireland-incorporated healthcare technology firm Medtronic assessed the MiniMed 780G system in historically challenging younger patients who do not meet glycemic goals. It was also assessed in individuals using a simplified meal announcement leveraging fixed carbohydrate quantities in place of precise carb calculations.
According to the latest data sets, the company’s proprietary Meal Detection technology supported Time in Range outcomes that were more than the consensus guidelines of 70%.
In addition, the insulin pump system reduced the amount of time spent in hyperglycaemia in children and adults, Medtronic said.
The first study of patients using a simplified meal announcement randomly assigned adults using the MiniMed 780G system into two groups, with some entering fixed carbs and some calculating a precise number of carbs.
The findings from the study revealed that patients using the fixed carb entry maintained international targets for glycemic control, including an A1c of 6.9% and TIR of 72.7% against 79.4% TIR in the precise entry group over six months.
Additionally, the simplified entry group lowered their time above 250mg/dL from 28.3% to 5.3% against 3.9% in the precise entry group at six months.
The second study of children ≤ 15 years in Europe and Latin America using the MiniMed 780G system with recommended settings of 100mg/dL and two-hour active insulin time (AIT) showed a TIR of 78%.
The healthcare technology firm said that a separate analysis of real-world evidence of children ≤ 15 years showed improved glycaemic performance in SmartGuard technology irrespective of baseline glycaemic control.
Medtronic diabetes EVP and president Que Dallara said: “We’re committed to pushing simplification of diabetes management as far as we can and are heartened to see the impact our MiniMed 780G system is having on both clinical and quality of life outcomes as evidenced by our randomised controlled ADAPT study and the growing body of real-world evidence from around the world.
“With each advancement, we’re working to reduce more of the burden that this disease demands and will continue to innovate to make life easier for those we have the privilege to support.”
